Fibrolamellar hepatocellular carcinoma - Prolonged survival with multimodality therapy

被引:50
|
作者
Maniaci, V. [1 ]
Davidson, B. R. [2 ]
Rolles, K. [2 ]
Dhillon, A. P. [3 ]
Hackshaw, A. [4 ,5 ]
Begent, R. H. [1 ]
Meyer, T. [1 ]
机构
[1] UCL Med Sch, Dept Oncol, London, England
[2] UCL Med Sch, Acad Dept Surg, London, England
[3] UCL Med Sch, Dept Pathol, London, England
[4] UCL Canc Trials Ctr, London, England
[5] Canc Res UK, London, England
来源
EJSO | 2009年 / 35卷 / 06期
关键词
Fibrolamellar; Hepatocellular; Chemotherapy; FDG-PET; Surgery; Liver cancer; CLINICOPATHOLOGICAL FEATURES; BINDING-CAPACITY; TUMOR; ADOLESCENTS; HEPATOMA; VARIANT; LIVER;
D O I
10.1016/j.ejso.2008.12.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: We report the clinical outcome for a series of tell patients with fibrolamellar hepatocellular treated with resection followed by close surveillance and aggressive management of relapse. Methods: The case notes for all patients treated at this institution since 1982 were reviewed and details of initial stage and management were extracted along with investigations and treatment of relapse. Time to relapse, overall survival and post-relapse survival were analysed. Results: Relapse occurred in all ten cases at a median of 2.2 (95% CI 0.9-2.7) years but, with a combination of re-resection, systemic chemotherapy and radiotherapy, the overall median survival was 9.3 (95% CI 3.0-18.5) years. One patient was disease free eight years after two resections for recurrent disease. Two of nine patients had a partial response to cisplatin and fluorouracil while three had stable disease. FDG-PET was positive for recurrence in three of four cases of relapse, and in one case detected recurrence in advance of CT. Conclusion: The early detection of relapse combined with multimodality therapy results in prolonged survival. Further improvements in systemic therapy are required to improve the prognosis in this disease. (C) 2008 Elsevier Ltd. All fights reserved.
引用
收藏
页码:617 / 621
页数:5
相关论文
共 50 条
  • [1] FIBROLAMELLAR HEPATOCELLULAR CARCINOMA: CLINICAL FEATURES AND SURVIVAL.
    Soloviy, Markiyan
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v75 - v75
  • [2] Fibrolamellar Hepatocellular Carcinoma
    Shahi, Niharika
    Chung, Andrew David
    [J]. APPLIED RADIOLOGY, 2023, 52 (02) : 48A - 48C
  • [3] Fibrolamellar Hepatocellular Carcinoma
    Liu, Shu
    Chan, Kwok Wah
    Wang, Bingyuan
    Qiao, Liang
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (10): : 2617 - 2624
  • [4] Fibrolamellar hepatocellular carcinoma
    Smith, Mitchell T.
    Blatt, Ellen R.
    Jedlicka, Paul
    Strain, John D.
    Fenton, Laura Z.
    [J]. RADIOGRAPHICS, 2008, 28 (02) : 609 - 613
  • [5] Fibrolamellar hepatocellular carcinoma
    Koudah, Sabrina
    El Mouhadi, Sanaa
    Arrive, Lionel
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2012, 36 (01) : 5 - 6
  • [6] PROLONGED SURVIVAL WITH HEPATOCELLULAR-CARCINOMA
    PENALBA, C
    LAROUZE, B
    MECHALI, D
    SAIMOT, G
    COULAUD, JP
    [J]. GASTROENTEROLOGY, 1982, 83 (05) : 1159 - 1159
  • [7] Managing fibrolamellar hepatocellular carcinoma
    Grandhi, Miral Sadaria
    Pawlik, Timothy M.
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (02): : 143 - 152
  • [8] FIBROLAMELLAR HEPATOCELLULAR-CARCINOMA
    FRIEDMAN, AC
    LICHTENSTEIN, JE
    GOODMAN, Z
    FISHMAN, EK
    SIEGELMAN, SS
    DACHMAN, AH
    [J]. RADIOLOGY, 1985, 157 (03) : 583 - 587
  • [9] Management of fibrolamellar hepatocellular carcinoma
    Chaudhari, Vikram A.
    Khobragade, Krunal
    Bhandare, Manish
    Shrikhande, Shailesh V.
    [J]. CHINESE CLINICAL ONCOLOGY, 2018, 7 (05)
  • [10] Downstaging and resection after neoadjuvant therapy for fibrolamellar hepatocellular carcinoma
    Fonseca, Gilton Marques
    Varella, Antonio Drauzio
    Coelho, Fabricio Ferreira
    Abe, Emerson Shigueaki
    Dumarco, Rodrigo Blanco
    Herman, Paulo
    [J]. WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2014, 6 (06): : 107 - 111